Susana Maria Campos, M.D.
This page shows the publications co-authored by Susana Campos and Stephen Cannistra.
Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.